A higher proportion of patients treated with tirzepatide achieved weight loss of 5% or greater (96% vs approximately 86%), 10% or greater (90% vs ~69%), and 15% or greater (78% vs ~50%)
The call to action is supported by another recent paper, published in a journal run by the American Heart Association, whose authors argue the effects of GLP-1 agonists on muscle health should be studied in a "more objective and comprehensive" way, especially given "the substantial numbers of patients who will likely be taking these medications well into the future." The study was published in The Lancet .
Cardiovascular Outcomes In patients with established cardiovascular disease and obesity, but without diabetes, semaglutide reduced major adverse cardiovascular events by 20 percent
Upper Arm: Inject into the back of the upper arm, where theres more fatty tissue
& Redmond, H
Dosage timing and consistency shape how semaglutide affects appetite, cravings, and GI symptoms, so gaps in coverage or sudden switches between a pen and a vial can produce weeks of noisy data that obscure underlying trends
